Reimbursement Support
Reimbursement Codes and Allowables
Reimbursement Guide
Patient Education
Prostate Diseases
  Prostate Cancer
  Benign Prostatic Hyperplasia (BPH)
  Prostatitis
  Helpful Links
Patient FAQs
Patient Information from Package Insert
Androgen Reduction Graph
Physician Information


  Bayer Global
  Bayer Corporate - USA
general conditions of use
privacy statement
imprint
© 2007 Bayer HealthCare Pharmaceuticals

 
Physician Support
Prostatitis - References		    
     
 
  1. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. page 14.
  2. National Institutes of Health, National Cancer Institute. Understanding Prostate Changes: A Health Guide for Men, 2004, page 5.
  3. National Institutes of Health, National Cancer Institute. Understanding Prostate Changes: A Health Guide for Men, 2004, page 5.
  4. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  5. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. Page 16.
  6. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. Page 16.
  7. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. Page 16.
  8. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. Page 16.
  9. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. Page 15.
  10. American Foundation for Urologic Disease. Prostate Health: Basic Facts for Better Health. What Every Man Should Know. Page 17.
  11. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  12. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  13. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  14. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  15. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  16. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  17. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  18. Prostatitis at the Prostate Center: Prostatitis Definition and Classification. Columbia University Department of Urology. Available at: http://cpmcnet.columbia.edu/dept/urology/prostatitis.html. Accessed January 1, 2005.
  


Back

Important Safety Considerations
Viadur is contraindicated in patients with hypersensitivity to Gn-RH, Gn-RH agonist analogs, or any of the components in Viadur.

Viadur is contraindicated in women and pediatric patients and was not studied in women or children.

Viadur, like other LH-RH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience a worsening of symptoms or onset of new symptoms including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, and spinal cord compression.

The most comment systemic side effects were hot flashes (67.9%), asthenia (7.6%), gynecomastia (6.9%), depression (5.3%), and sweating (5.3%). The most common local side effects were bruising (34.6%) and burning (5.6%).

Distributed and Marketed by:
Manufactured by:

Bayer HealthCare Pharmaceuticals
6 West Belt, Wayne, NJ 07470 USA

© Copyright 2007 Bayer HealthCare Pharmaceuticals. Viadur is a trademark of ALZA Corporation under license to Bayer HealthCare Pharmaceuticals. DUROS® is a registered trademark of ALZA Corporation.

The information provided on Bayer products is only intended for the United States audience. Regulatory requirements, regulations, laws, and distribution of information about drug products may vary from country to country. Product names and indications (product uses) also may be different in different countries. The prescribing information provided here is based on United States labeling and may not be appropriate outside of the United States.